In this regard, the anti-HF effects of histamine H2 receptor antagonists (H2RAs) consequently gained particular attention in the following related clinical investigations, based on which it was suggested that H2RAs had beneficial effects on short- and medium-term outcomes of HF patients (Adelborg et al., 2018; Zhang et al., 2018; Huang et al., 2022) and exhibited relatively safe profile in cardiovascular system (Meng et al., 2023). The gene discussed is HRH2; the disease is hydrops fetalis.